Sandoz Group Framtida tillväxt
Future kriterier kontrolleras 3/6
Sandoz Group förväntas öka intäkter och intäkter med 17% respektive 5.2% per år. EPS förväntas tillväxt med 17.1% per år. Avkastningen på eget kapital förväntas bli 17.8% om 3 år.
Viktig information
17.0%
Tillväxttakt i vinsten
17.09%
Tillväxttakt för EPS
| Pharmaceuticals vinsttillväxt | 10.3% |
| Intäkternas tillväxttakt | 5.2% |
| Framtida avkastning på eget kapital | 17.82% |
| Bevakning av analytiker | Good |
| Senast uppdaterad | 08 May 2026 |
Senaste uppdateringarna om framtida tillväxt
Recent updates
Uppdatering av berättelse • May 01
SDZ: Mixed Rating Shifts And Biosimilar Deals Will Shape Future P/E
The updated analyst price target for Sandoz Group has been revised by approximately CHF 1 higher, reflecting modestly adjusted assumptions around fair value, revenue growth, profit margins and future P/E as analysts balance recent target changes and rating shifts across major banks. Analyst Commentary Recent Street research around Sandoz Group shows a mix of optimism on the company’s long term potential and caution on how current pricing and expectations line up with execution risks.
Uppdatering av berättelse • Apr 16
SDZ: Elevated Expectations Will Test Execution On Biosimilar Expansion Plans
Analysts have raised the Sandoz Group price target by roughly CHF 2 per share, reflecting a higher assumed fair value. This is supported by a series of recent CHF 3 to CHF 9 target increases from major banks and generally constructive views, despite some rating downgrades.
Uppdatering av berättelse • Apr 01
SDZ: Future P/E Repricing And Biosimilar Expansion May Drive Re Rating
Analysts have lifted the price target for Sandoz Group from CHF 60.37 to CHF 81.99, citing recent initiations, upgrades and target increases that highlight a higher assumed future P/E multiple and slightly improved profit margin expectations, despite more measured revenue growth assumptions. Analyst Commentary Recent Street research on Sandoz Group presents a mixed picture, but there is a clear strand of optimism around execution, earnings quality and the scope for the shares to support higher valuation multiples.Uppdatering av berättelse • Mar 18
SDZ: Mixed Rating Shifts And Biosimilar Expansion Will Shape Future P/E
Analysts have lifted the Fair Value estimate for Sandoz Group from CHF 62.57 to CHF 65.45. This reflects a series of higher Street price targets around CHF 62 to CHF 75 and updated assumptions for modestly higher revenue growth, a slightly lower profit margin profile, and a higher future P/E multiple.Uppdatering av berättelse • Mar 04
SDZ: Mixed Rating Shifts And Biosimilar Pipeline Progress Will Shape Future P/E
Analysts have lifted their fair value estimate for Sandoz to about CHF 63, reflecting updated assumptions for slightly lower revenue growth, a higher profit margin and a modestly lower future P/E, along with recent mixed rating changes and higher price targets in the CHF 70 to CHF 75 range. Analyst Commentary Recent Street research on Sandoz shows a mix of optimism and caution, with price targets now clustering in the CHF 70 to CHF 75 range and ratings shifting closer to neutral.Uppdatering av berättelse • Feb 18
SDZ: Richer Future P/E Assumptions Will Test Biosimilar Execution Confidence
Our latest narrative update on Sandoz Group reflects a higher implied fair value of CHF 58.42, up from CHF 52.75, supported by recent analyst price target increases and a willingness to assign a richer future P/E multiple. Analyst Commentary Recent Street research around Sandoz Group has centered on a series of price target revisions and at least one rating upgrade, which together frame how the analyst community is thinking about valuation, execution risk, and growth potential.Uppdatering av berättelse • Feb 03
SDZ: Elevated Expectations Will Confront Ongoing Execution And Manufacturing Setbacks
Analysts have raised their average price target on Sandoz Group by CHF 3 to CHF 60, citing updated assumptions for revenue growth, profit margins and future P/E, in line with recent target increases from several major banks. Analyst Commentary Recent Street research on Sandoz Group has largely focused on recalibrating price targets to reflect updated views on revenue growth, profitability and valuation multiples.Uppdatering av berättelse • Jan 20
SDZ: Rising Biosimilar Pipeline Will Face Ongoing Execution And Manufacturing Risks
Narrative Update The updated analyst price target for Sandoz Group reflects a modestly lower fair value estimate alongside slightly higher revenue growth and profit margin assumptions. Recent Street research citing price target moves to CHF 60 and CHF 70 indicates that analysts see room for the shares to better reflect these revised expectations.Uppdatering av berättelse • Jan 06
SDZ: Elevated Biosimilar Ambitions Will Face Ongoing Execution And Manufacturing Risks
Analysts have lifted their average price targets on Sandoz Group into a CHF 49 to CHF 70 range, and our updated fair value of CHF 44.42 nudges slightly lower as higher assumed profit margins and revenue growth are offset by a reduced future P/E multiple. Analyst Commentary Recent Street research on Sandoz Group shows a cluster of higher price targets, with targets in the CHF 49 to CHF 70 range.Uppdatering av berättelse • Dec 21
SDZ: Elevated Expectations Will Face Execution Risks In Biosimilars Expansion
Sandoz Group's analyst price target has been lifted by roughly CHF 6.50 to around CHF 60, as analysts now factor in stronger revenue growth, modestly higher profit margins, and a richer forward valuation multiple. Analyst Commentary Recent Street research has been broadly constructive on Sandoz Group, with several major firms lifting their price targets into the CHF 49 to CHF 60 range and maintaining positive ratings.Uppdatering av berättelse • Dec 07
SDZ: Biosimilar Launch Execution Will Shape Future Multiple And Risk Balance
Sandoz Group’s analyst price target has been nudged higher, with fair value estimates rising by about CHF 1.10 to CHF 52.75 as analysts point to sustained revenue growth expectations and a modestly higher future P E multiple, despite slightly lower margin forecasts. Analyst Commentary Bullish analysts have recently raised their price targets into the CHF 55 to CHF 60 range, signaling growing confidence that Sandoz can sustain above market growth and support a higher valuation multiple.Uppdatering av berättelse • Nov 23
SDZ: Sustained Revenue Momentum And Margin Focus Will Shape Fair Value Ahead
The analyst consensus price target for Sandoz Group has increased to CHF 60 from CHF 55. Analysts cite improved margin outlook and sustained revenue growth as key factors supporting the upward revision.Uppdatering av berättelse • Nov 09
SDZ: Recent US Launch and European Expansion Will Influence Near-Term Performance
The average analyst price target for Sandoz Group has increased from CHF 50.33 to CHF 52.05, reflecting improved revenue growth forecasts and recent supportive analyst research updates. Analyst Commentary Recent analyst updates reflect a mix of optimism and caution regarding Sandoz Group's valuation, growth prospects, and execution.Uppdatering av berättelse • Oct 26
Future Opportunities Will Be Unlocked Through Expanding Pipeline And Global Market Reach
The analyst consensus price target for Sandoz Group rose modestly, increasing from CHF 50.20 to CHF 50.33. Analysts cited stronger revenue growth and improving profit margins in their updated outlooks.Uppdatering av berättelse • Oct 12
Biosimilar Pipeline And Global Expansion Will Unlock Future Opportunities
The analyst price target for Sandoz Group has increased by CHF 0.81. This reflects positive sentiment from analysts who cite strong revenue growth and continued profitability improvements as supporting factors.Ny berättelse • Aug 17
Biosimilar Pipeline And Global Expansion Will Unlock Future Opportunities
Key Takeaways Accelerated biosimilar launches, improved manufacturing, and strong market share are driving margin expansion and long-term profitability. Strategic focus on international growth and a robust product pipeline positions the company for sustainable earnings momentum.Analysartikel • Jun 25
Sentiment Still Eluding Sandoz Group AG (VTX:SDZ)
You may think that with a price-to-sales (or "P/S") ratio of 2.2x Sandoz Group AG ( VTX:SDZ ) is definitely a stock...Prognoser för vinst- och omsättningstillväxt
| Datum | Intäkter | Intäkter | Fritt kassaflöde | Kassaflöde från rörelsen | Genomsnittligt Antal analytiker |
|---|---|---|---|---|---|
| 12/31/2028 | 13,341 | 1,905 | 1,600 | 2,176 | 13 |
| 12/31/2027 | 12,737 | 1,697 | 1,335 | 2,008 | 15 |
| 12/31/2026 | 12,165 | 1,374 | 725 | 1,493 | 14 |
| 12/31/2025 | 11,157 | 914 | 836 | 1,594 | N/A |
| 9/30/2025 | 10,872 | 571 | 548 | 1,272 | N/A |
| 6/30/2025 | 10,587 | 227 | 259 | 950 | N/A |
| 3/31/2025 | 10,486 | 114 | 168 | 803 | N/A |
| 12/31/2024 | 10,384 | N/A | 76 | 656 | N/A |
| 9/30/2024 | 10,248 | -4 | -28 | 581 | N/A |
| 6/30/2024 | 10,111 | -8 | -133 | 506 | N/A |
| 3/31/2024 | 10,045 | 35 | -195 | 434 | N/A |
| 12/31/2023 | 9,979 | 77 | -258 | 362 | N/A |
| 9/30/2023 | 9,770 | 345 | 136 | 664 | N/A |
| 6/30/2023 | 9,561 | 613 | 530 | 966 | N/A |
| 3/31/2023 | 9,434 | 731 | 679 | 1,095 | N/A |
| 12/31/2022 | 9,306 | 848 | 828 | 1,223 | N/A |
| 12/31/2021 | 9,678 | 908 | 1,000 | 1,354 | N/A |
| 12/31/2020 | 9,658 | 462 | 813 | 1,098 | N/A |
Analytiker Framtid Tillväxt Prognoser
Intäkter kontra sparande: SDZ s prognostiserade vinsttillväxt ( 17% per år) är över sparkvoten ( 0.6% ).
Resultat vs marknad: SDZ s intäkter ( 17% per år) förväntas växa snabbare än marknaden för Swiss ( 10.9% per år).
Höga tillväxtresultat: SDZ s intäkter förväntas växa, men inte avsevärt.
Intäkt vs marknad: SDZ s intäkter ( 5.2% per år) förväntas växa snabbare än Swiss marknaden ( 4.9% per år).
Hög tillväxtintäkter: SDZ s intäkter ( 5.2% per år) förväntas växa långsammare än 20% per år.
Tillväxtprognoser för vinst per aktie
Framtida avkastning på eget kapital
Framtida ROE: SDZ s avkastning på eget kapital förväntas bli låg om 3 år ( 17.8 %).
Upptäck tillväxtföretag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/22 06:02 |
| Aktiekurs vid dagens slut | 2026/05/22 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Sandoz Group AG bevakas av 37 analytiker. 15 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Emily Field | Barclays |
| James Gordon | Barclays |
| Sidhartha Modi | Barclays |